Farallon Capital Management
VC Fund
San Francisco, United States
Farallon Capital Management is a VC fund in San Francisco focused on Biotechnology and Health Care. Farallon Capital Management, L.L.C. is an American capital management firm that manages funds on behalf of institutions and individuals with significant capital. Based in San Francisco, the firm was founded by Thomas F. Steyer in March of 1986. As of September 2008, it has around 150 employees.While it invests across the capital structure andin all asset classes, a large amount of its investments are in risk arbitrage, restructuring and recapitalization. Investments include public and private debt and equity securities, direct investments in private companies, and real estate. Farallon's real estate investments span the United States, Europe, Latin America and India.
- Total investments:
- 121
- Last investment:
- Lead investor:
- 21%
- Fund size:
- $650M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Farallon Capital Management invests in
Stages Farallon Capital Management invests in
Countries Farallon Capital Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series C
- $25M–$165M
- Series D
- $44M–$300M
- Post-IPO Equity
- $70M–$325M
Investment Focus
Industry
- Biotechnology 56 (46%)
- Health Care 41 (34%)
- Therapeutics 19 (16%)
- Pharmaceutical 18 (15%)
- Medical 17 (14%)
Stage
- Post-IPO Equity 27 (22%)
- Series C 16 (13%)
- Series D 16 (13%)
- Series B 15 (12%)
- Series A 9 (7%)
Country
- United States 55 (45%)
- China 11 (9%)
- India 3 (2%)
- Germany 3 (2%)
- United Kingdom 3 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Evan J. Tato
Managing DirectorSan Francisco
|
Managing DirectorSan Francisco | Total investments: 0 | Find email | |
Charles Gunawan
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
David Kim
Partner
|
Partner | Total investments: 0 | Find email | |
|
David M. Gliklich
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Edward S. Chung
Managing DirectorSan Francisco
|
Managing DirectorSan Francisco | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovasculardisease, enabling medical practitioners to treat patients and improve their lives. | $275M / Series F / Sep 09, 2026 | ||
| Hibob was founded in 2015 to modernize HR tech. Hibob's intuitive and data-driven platform, bob, was built for the way people work today: globally, remotely, and collaboratively. Since its launch, bob has achieved consecutive triple-digit year-over-year growth, and become the HRIS of choice for more than 1,000 modern, midsize and multinationalcompanies who understand that a powerful, agile HR tech suite is mission critical and a key driver of organizational success. Fast-growing companies across the globe rely upon bob to help HR and managers connect, engage, develop and retain top talent. | $166M / Private Equity / Sep 01, 2026 | ||
| LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. Its approach is to create a research-focused organization dedicated to generating novel intellectual propertyaround improved versions of these former best-selling drugs. The Company's lead asset is LB-102 (n-Methyl amisulpride) a novel, patented version of amisulpride, one of the most effective drugs ever developed for the treatment of schizophrenia. | $150M / Post-IPO Equity / Jul 29, 2026 | ||
| Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $240M / Post-IPO Equity / Jul 20, 2026 | ||
| Shapoorji Pallonji & Co. Ltd. is just one of the jewels in the SP Group's crown. | $2.3B / Debt Financing / Jul 10, 2026 | ||
| Assembly Biosciences is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome. Assembly‘sHBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates. | $115M / Post-IPO Equity / May 22, 2026 | ||
| InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.In April 2018, InflaRx conducted a USD 117 million totalgross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany. | $150M / Post-IPO Equity / May 06, 2026 | ||
| Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASNinhibitors. | $175M / Post-IPO Equity / Apr 27, 2026 | ||
| Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.andits also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases. | $150M / Post-IPO Equity / Apr 22, 2026 | ||
| Isemia is a Real Estate company builds and oversees a portfolio of properties devoted to medical facilities. | $886.2M / Private Equity / Jan 14, 2026 | ||
| See all 121 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Farallon Capital Management invest in?
Farallon Capital Management invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series C stage. Most of the 121 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Farallon Capital Management's check size?
Farallon Capital Management typically joins rounds of $25M–$165M at Series C, $44M–$300M at Series D and $70M–$325M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Farallon Capital Management participates in.
How do I contact Farallon Capital Management?
Public channels for Farallon Capital Management include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Farallon Capital Management?
The team at Farallon Capital Management includes Evan J. Tato (Managing DirectorSan Francisco), Charles Gunawan (Managing Director) and David Kim (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
